These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32848385)

  • 1. Enhanced Anti-Brain Metastasis from Non-Small Cell Lung Cancer of Osimertinib and Doxorubicin Co-Delivery Targeted Nanocarrier.
    Wang X; Mao W; Wang Z; Li X; Xiong Y; Lu H; Wang X; Yin H; Cao X; Xin H
    Int J Nanomedicine; 2020; 15():5491-5501. PubMed ID: 32848385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
    Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced blood-brain barrier penetration and glioma therapy mediated by T7 peptide-modified low-density lipoprotein particles.
    Liang M; Gao C; Wang Y; Gong W; Fu S; Cui L; Zhou Z; Chu X; Zhang Y; Liu Q; Zhao X; Zhao B; Yang M; Li Z; Yang C; Xie X; Yang Y; Gao C
    Drug Deliv; 2018 Nov; 25(1):1652-1663. PubMed ID: 30394123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.
    Yun J; Hong MH; Kim SY; Park CW; Kim S; Yun MR; Kang HN; Pyo KH; Lee SS; Koh JS; Song HJ; Kim DK; Lee YS; Oh SW; Choi S; Kim HR; Cho BC
    Clin Cancer Res; 2019 Apr; 25(8):2575-2587. PubMed ID: 30670498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
    Martinez-Marti A; Felip E; Matito J; Mereu E; Navarro A; Cedrés S; Pardo N; Martinez de Castro A; Remon J; Miquel JM; Guillaumet-Adkins A; Nadal E; Rodriguez-Esteban G; Arqués O; Fasani R; Nuciforo P; Heyn H; Villanueva A; Palmer HG; Vivancos A
    Ann Oncol; 2017 Oct; 28(10):2451-2457. PubMed ID: 28961841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A natural anthraquinone derivative shikonin synergizes with AZD9291 against wtEGFR NSCLC cells through reactive oxygen species-mediated endoplasmic reticulum stress.
    Hu X; Zhang ZY; Wu LW; Zeng LH; Chen H; Zhu HJ; Zhang JK; Shao J; Zhang C; Li YL; Lin NM
    Phytomedicine; 2020 Mar; 68():153189. PubMed ID: 32070867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
    Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
    Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP
    Katsuya Y; Miyake K; Higuchi T; Oshiro H; Sugisawa N; Singh SR; Goto Y; Zhao M; Hoffman RM
    In Vivo; 2020; 34(3):1027-1030. PubMed ID: 32354888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesoporous Graphene Oxide Nanocomposite Effective for Combined Chemo/Photo Therapy Against Non-Small Cell Lung Cancer.
    Zhang P; Zheng L; Zhang X; Liu M; Li M; Zhang M; Wu JL; Choi MMF; Bian W
    Int J Nanomedicine; 2024; 19():7493-7508. PubMed ID: 39081895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers.
    Jin Y; Wang Y; Liu X; Zhou J; Wang X; Feng H; Liu H
    Drug Des Devel Ther; 2020; 14():5205-5215. PubMed ID: 33268983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Combination of Doxorubicin and Paclitaxel Delivered by Blood Brain Barrier and Glioma Cells Dual Targeting Liposomes for Chemotherapy of Brain Glioma.
    Chen X; Yuan M; Zhang Q; Ting Yang Y; Gao H; He Q
    Curr Pharm Biotechnol; 2016; 17(7):636-50. PubMed ID: 27033513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR
    Yin W; Zhao Y; Kang X; Zhao P; Fu X; Mo X; Wang Y; Huang Y
    Theranostics; 2020; 10(14):6122-6135. PubMed ID: 32483443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrin α
    Huang CW; Chuang CP; Chen YJ; Wang HY; Lin JJ; Huang CY; Wei KC; Huang FT
    J Nanobiotechnology; 2021 Jun; 19(1):180. PubMed ID: 34120610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal Carrier Conjugated to APP-Derived Peptide for Brain Cancer Treatment.
    Gabay M; Weizman A; Zeineh N; Kahana M; Obeid F; Allon N; Gavish M
    Cell Mol Neurobiol; 2021 Jul; 41(5):1019-1029. PubMed ID: 33025416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1.
    Zhao R; Yin W; Yu Q; Mao Y; Deng Q; Zhang K; Ma S
    Bioengineered; 2022 Jan; 13(1):331-344. PubMed ID: 34738874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs.
    Colclough N; Chen K; Johnström P; Strittmatter N; Yan Y; Wrigley GL; Schou M; Goodwin R; Varnäs K; Adua SJ; Zhao M; Nguyen DX; Maglennon G; Barton P; Atkinson J; Zhang L; Janefeldt A; Wilson J; Smith A; Takano A; Arakawa R; Kondrashov M; Malmquist J; Revunov E; Vazquez-Romero A; Moein MM; Windhorst AD; Karp NA; Finlay MRV; Ward RA; Yates JWT; Smith PD; Farde L; Cheng Z; Cross DAE
    Clin Cancer Res; 2021 Jan; 27(1):189-201. PubMed ID: 33028591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy.
    Riaz MK; Zhang X; Wong KH; Chen H; Liu Q; Chen X; Zhang G; Lu A; Yang Z
    Int J Nanomedicine; 2019; 14():2879-2902. PubMed ID: 31118613
    [No Abstract]   [Full Text] [Related]  

  • 18. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier.
    Ma W; Sun J; Xu J; Luo Z; Diao D; Zhang Z; Oberly PJ; Minnigh MB; Xie W; Poloyac SM; Huang Y; Li S
    Theranostics; 2020; 10(6):2463-2478. PubMed ID: 32194813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo.
    Wang XS; Zhang L; Li X; Kong DJ; Hu XC; Ding XZ; Yang JQ; Zhao MQ; He Y; Lam KS; Gao SG; Lin TY; Li Y
    Nanomedicine (Lond); 2018 May; 13(10):1107-1120. PubMed ID: 29874151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.
    Arvanitis CD; Askoxylakis V; Guo Y; Datta M; Kloepper J; Ferraro GB; Bernabeu MO; Fukumura D; McDannold N; Jain RK
    Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8717-E8726. PubMed ID: 30150398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.